molnupiravir
Selected indexed studies
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. (N Engl J Med, 2022) [PMID:34914868]
- Molnupiravir: First Approval. (Drugs, 2022) [PMID:35184266]
- Molnupiravir: an antiviral drug against COVID-19. (Arch Virol, 2023) [PMID:37710056]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. (2022) pubmed
- Molnupiravir: First Approval. (2022) pubmed
- Molnupiravir: an antiviral drug against COVID-19. (2023) pubmed
- Molnupiravir. (2012) pubmed
- Molnupiravir. (1994) pubmed
- Molnupiravir and Its Antiviral Activity Against COVID-19. (2022) pubmed
- Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. (2023) pubmed
- Molnupiravir: Mechanism of action, clinical, and translational science. (2024) pubmed
- Molnupiravir in COVID-19: A Scoping Review. (2022) pubmed
- Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series. (2023) pubmed